Bibliography
- Grasso G, Sfacteria A. The many faces of erythropoietin: from erythropoiesis to a rational neuroprotective strategy. Expert Opin Investig Drugs 2008;17(10):1407-9
- Lapchak PA. Carbamylated erythropoietin to treat neuronal injury: new development strategies. Expert Opin Investig Drugs 2008;17(8):1175-86
- Lapchak PA, Araujo DM. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin Emerging Drugs 2007;12(3):389-406
- Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs 2002;11(11):1623-32
- Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerging Drugs 2007;12(1):97-112
- NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7
- O'Collins VE, MacLeod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59(3):467-77
- Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 2008;39(6):1751-8
- Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8(8):495-505